HC Wainwright Reiterates Buy Rating for Achieve Life Sciences (NASDAQ:ACHV)

Achieve Life Sciences (NASDAQ:ACHV)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $12.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 135.29% from the stock’s previous close.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Achieve Life Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Achieve Life Sciences Trading Up 6.0%

NASDAQ:ACHV opened at $5.10 on Thursday. The company has a market cap of $271.47 million, a P/E ratio of -3.92 and a beta of 1.96. The stock’s fifty day moving average price is $3.93 and its two-hundred day moving average price is $4.34. Achieve Life Sciences has a 1 year low of $1.96 and a 1 year high of $6.03. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.39 and a quick ratio of 4.39.

Achieve Life Sciences (NASDAQ:ACHV) last posted its earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.01). As a group, analysts expect that Achieve Life Sciences will post -1.17 EPS for the current year.

Institutional Trading of Achieve Life Sciences

Institutional investors have recently modified their holdings of the company. Alpine Global Management LLC purchased a new stake in Achieve Life Sciences in the fourth quarter worth about $415,000. KVP Capital Advisors LP purchased a new stake in Achieve Life Sciences in the fourth quarter worth about $2,298,000. Millennium Management LLC lifted its holdings in Achieve Life Sciences by 472.3% in the fourth quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock worth $6,755,000 after buying an additional 1,121,614 shares during the period. 683 Capital Management LLC purchased a new stake in Achieve Life Sciences in the fourth quarter worth about $1,068,000. Finally, Jump Financial LLC purchased a new stake in Achieve Life Sciences in the fourth quarter worth about $104,000. 33.52% of the stock is currently owned by hedge funds and other institutional investors.

Achieve Life Sciences News Roundup

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: Achieve secured a private placement for up to $354 million (≈$180M upfront with up to $174M from milestone warrants), providing funding to support a Phase 3 e‑cigarette cessation trial, commercialization planning and working capital — a major de‑risking of near‑term cash needs. Private Placement Announcement
• Positive Sentiment: Andrew D. Goldberg, MD has been named CEO and two experienced life‑science investors (Lucian Iancovici, MD and Aaron E. Royston, MD) were added to the board — signaling stronger commercial and capital markets leadership ahead of potential approval and launch. CEO & Board Appointments
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and set a $12 price target, which provides a bullish analyst voice and likely boosts investor confidence in ACHV’s commercial upside if cytisinicline is approved. Analyst Rating Reaffirmed
• Neutral Sentiment: Market reaction: coverage notes ACHV is having one of its strongest intraday gains in years as news flows — this reflects momentum trading and heightened attention rather than new clinical data. Market Reaction / News Coverage
• Negative Sentiment: Potential dilution and conditional financing risk: the deal issues ~49.4M common shares (and pre‑funded warrants) at $3.635 and accompanying milestone warrants exercisable near $3.51; unregistered securities and warrant terms could dilute current holders if exercised, and the ultimate $174M is contingent on FDA approval triggers. Also, ACHV’s value remains binary on the upcoming FDA decision — a negative outcome would remove the financing upside and pressure the stock. Financing Details & Risks

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.